Portal de Periódicos da CAPES

Re: The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count, by Romani AA, Borghetti AF, Del Rio P, et al.

2006; Wiley; Volume: 93; Issue: 6 Linguagem: Inglês

10.1002/jso.20457

1096-9098

Axel Kleespies,

Cell Adhesion Molecules Research

Journal of Surgical OncologyVolume 93, Issue 6 p. 435-436 Editorial Re: The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count, by Romani AA, Borghetti AF, Del Rio P, et al. Axel Kleespies MD, Corresponding Author Axel Kleespies MD [email protected] Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, GermanyDepartment of Surgery, Klinikum Grosshadern, Marchioninistrasse 15, 81667 Munich, Germany.Search for more papers by this author Axel Kleespies MD, Corresponding Author Axel Kleespies MD [email protected] Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University, Munich, GermanyDepartment of Surgery, Klinikum Grosshadern, Marchioninistrasse 15, 81667 Munich, Germany.Search for more papers by this author First published: 13 April 2006 https://doi.org/10.1002/jso.20457AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Guba M, Seeliger H, Kleespies A, et al.: Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 2004; 19: 510–517. 2 Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–2342. 3 Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145–147. 4 Weidner N, Semple JP, Welch WR, et al.: Tumor angiogenesis and metastasis—Correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8. 5 Hasan J, Byers R, Jayson GC: Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86: 1566–1577. 6 Romani AA, Borghetti AF, Del Rio P, et al.: The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol 2006; 93: 446–455. 7 Duff SE, Li C, Garland JM, et al.: CD105 is important for angiogenesis: Evidence and potential applications. FASEB J 2003; 17: 984–992. 8 Fonsatti E, Altomonte M, Nicotra MR, et al.: Endoglin (CD105): A powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003; 22: 6557–6563. 9 Gasparini G, Brooks PC, Biganzoli E, et al.: Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625–2634. 10 Saad RS, Liu YL, Nathan G, et al.: Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004; 17: 197–203. 11 Li C, Gardy R, Seon BK, et al.: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003; 88: 1424–1431. Volume93, Issue61 May 2006Pages 435-436 ReferencesRelatedInformation